Actinium Pharmaceuticals, Inc. (FRA:7AY1)

Germany flag Germany · Delayed Price · Currency is EUR
1.215
-0.004 (-0.33%)
At close: Jan 9, 2026
-8.30%
Market Cap37.28M
Revenue (ttm)76.71K
Net Income (ttm)-29.49M
Shares Outn/a
EPS (ttm)-0.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume124
Open1.215
Previous Close1.219
Day's Range1.215 - 1.215
52-Week Range0.998 - 1.821
Betan/a
RSI49.23
Earnings DateMar 30, 2026

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic ... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Sandesh Seth
Employees 37
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 7AY1
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.